H3N2 Infection - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 66 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

H3N2 Infection - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'H3N2 Infection - Pipeline Review, H2 2014', provides an overview of the H3N2 Infection's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for H3N2 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H3N2 Infection and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of H3N2 Infection
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for H3N2 Infection and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the H3N2 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the H3N2 Infection pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for H3N2 Infection
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding H3N2 Infection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
H3N2 Infection Overview 7
Therapeutics Development 8
Pipeline Products for H3N2 Infection - Overview 8
Pipeline Products for H3N2 Infection - Comparative Analysis 9
H3N2 Infection - Therapeutics under Development by Companies 10
H3N2 Infection - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
H3N2 Infection - Products under Development by Companies 14
H3N2 Infection - Companies Involved in Therapeutics Development 15
Johnson & Johnson 15
Autoimmune Technologies, LLC 16
Inovio Pharmaceuticals, Inc. 17
Takeda Pharmaceutical Company Limited 18
Crucell N.V. 19
NanoViricides, Inc. 20
Colby Pharmaceutical Company 21
AlphaVax, Inc. 22
REPLICor Inc. 23
Vaxart, Inc. 24
Cure Lab, Inc. 25
H3N2 Infection - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
VX-787 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
AVX-502 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
bordetella pertussis vaccine [BPZE1] - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
NVINF-2 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
REP-9 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Influenza VLP Vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Flufirvitide-3 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
JVRS-100 + Universal Influenza Vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
NVINF-1 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ID-38 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
CR-9114 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Recombinant Vector Vaccine for H3N2 Seasonal Influenza - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
C-05 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Gamma-Flu - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
DNA Vaccine for H3N2 Influenza - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
CLVax-1.0 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
H3N2 Infection - Recent Pipeline Updates 54
H3N2 Infection - Dormant Projects 60
H3N2 Infection - Discontinued Products 61
H3N2 Infection - Product Development Milestones 62
Featured News & Press Releases 62
Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100 62
Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza 62
Jul 26, 2012: Novartis Begins Shipment Of Fluvirin Seasonal Influenza Vaccine In US For 2012-2013 Influenza Season 63
Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 66
Disclaimer 66

List of Tables
Number of Products under Development for H3N2 Infection, H2 2014 8
Number of Products under Development for H3N2 Infection - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
H3N2 Infection - Pipeline by Johnson & Johnson, H2 2014 15
H3N2 Infection - Pipeline by Autoimmune Technologies, LLC, H2 2014 16
H3N2 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 17
H3N2 Infection - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 18
H3N2 Infection - Pipeline by Crucell N.V., H2 2014 19
H3N2 Infection - Pipeline by NanoViricides, Inc., H2 2014 20
H3N2 Infection - Pipeline by Colby Pharmaceutical Company, H2 2014 21
H3N2 Infection - Pipeline by AlphaVax, Inc., H2 2014 22
H3N2 Infection - Pipeline by REPLICor Inc., H2 2014 23
H3N2 Infection - Pipeline by Vaxart, Inc., H2 2014 24
H3N2 Infection - Pipeline by Cure Lab, Inc., H2 2014 25
Assessment by Monotherapy Products, H2 2014 26
Assessment by Combination Products, H2 2014 27
Number of Products by Stage and Target, H2 2014 29
Number of Products by Stage and Mechanism of Action, H2 2014 31
Number of Products by Stage and Route of Administration, H2 2014 33
Number of Products by Stage and Molecule Type, H2 2014 35
H3N2 Infection Therapeutics - Recent Pipeline Updates, H2 2014 54
H3N2 Infection - Dormant Projects, H2 2014 60
H3N2 Infection - Discontinued Products, H2 2014 61